141 related articles for article (PubMed ID: 33868471)
1. Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells.
Hu CS; Huang JH; Yang DL; Xu C; Xu ZG; Tan HB; Chen ZZ
Oncol Lett; 2021 Jun; 21(6):433. PubMed ID: 33868471
[TBL] [Abstract][Full Text] [Related]
2. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.
Zhou L; Lv X; Yang J; Zhu Y; Wang Z; Xu T
Oncol Lett; 2018 Aug; 16(2):2533-2538. PubMed ID: 30008942
[TBL] [Abstract][Full Text] [Related]
4. Astragalus polysaccharides reverse gefitinib resistance by inhibiting mesenchymal transformation in lung adenocarcinoma cells.
Wei J; Li Y; Xu B; Yu J
Am J Transl Res; 2020; 12(5):1640-1657. PubMed ID: 32509166
[TBL] [Abstract][Full Text] [Related]
5. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
[TBL] [Abstract][Full Text] [Related]
6. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154
[TBL] [Abstract][Full Text] [Related]
7. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
8. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
9. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
10. ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Liu XL; Zhang XT; Meng J; Zhang HF; Zhao Y; Li C; Sun Y; Mei QB; Zhang F; Zhang T
Oncotarget; 2017 Aug; 8(33):54265-54276. PubMed ID: 28903339
[TBL] [Abstract][Full Text] [Related]
11. Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
Hsieh YS; Liao CH; Chen WS; Pai JT; Weng MS
J Cell Biochem; 2017 Dec; 118(12):4639-4651. PubMed ID: 28485480
[TBL] [Abstract][Full Text] [Related]
12. WZ4003 sensitizes non-small cell lung cancer cells to gefitinib via inhibition of ARK5 and epithelial-to-mesenchymal transition.
Chen J; Zhang S; Zheng X; Mao J; Xie S; Chen W; Ran X
Am J Transl Res; 2020; 12(11):7377-7385. PubMed ID: 33312374
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.
Li YQ; Liu YS; Ying XW; Zhou HB; Wang Z; Wu SC; Yan JP; Jing YT; Yang Y
Biotechnol Prog; 2018 Jan; 34(1):196-205. PubMed ID: 28960861
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
15. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
17. Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis.
Gu Y; Li T; Kapoor A; Major P; Tang D
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32752094
[TBL] [Abstract][Full Text] [Related]
18. ING5 inhibits lung cancer invasion and epithelial-mesenchymal transition by inhibiting the WNT/β-catenin pathway.
Liu XL; Meng J; Zhang XT; Liang XH; Zhang F; Zhao GR; Zhang T
Thorac Cancer; 2019 Apr; 10(4):848-855. PubMed ID: 30810286
[TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
20. Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells.
Luo W; Liu Q; Jiang N; Li M; Shi L
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31467176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
